Drug Profile
Research programme: Anti-O-acetylated-GD2 monoclonal antibodies - OGD2 Pharma
Alternative Names: Anti-O-acetylated-GD2 monoclonal antibody - OGD2 Pharma; OGD 201Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator OGD2 Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Sep 2023 Anti-O-acetylated-GD2 monoclonal antibodies are still in preclinical trials for Cancer in USA (OGD2 website, Sep 2023)
- 29 Nov 2016 OGD2 Pharma and University of Zurich enter research collaboration for development of OAcGD2 antibodies
- 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Monoclonal antibodies against OAcGD2 for the treatment of Cancer